Hydroxyethyl-Starch Solutions To Be Pulled From EU Market
Member States Can Temporarily Delay Suspension Citing Public Health Considerations
Hydroxyethyl-starch solutions are being suspended from the EU following the failure of several safety measures that were introduced to prevent their use in certain high-risk patient groups.
You may also be interested in...
The introduction of direct reporting of adverse drug reactions by patients in Europe appears to have had the desired effect: in 2013, the number of ADRs reported by patients within the European Economic Area rose by more than 50% as a result of greater public awareness of the importance of such reporting.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.